Cutaneous T-Cell Lymphoma Recurrent Recruiting Phase 2 Trials for Devimistat (DB12109)

Also known as: T-Cell Lymphoma Relapsed / Recurrent T-Cell Lymphoma / Recurrent Cutaneous T-cell lymphoma / T-cell lymphoma recurrent / Relapsed T-Cell Lymphoma / T-cell lymphoma NOS recurrent

IndicationStatusPhase
DBCOND0136063 (Cutaneous T-Cell Lymphoma Recurrent)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04217317CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin LymphomaTreatment